Telomerase expression in normal epithelium, reactive atypia, squamous dysplasia, and squamous cell carcinoma of the uterine cervix

American Journal of Clinical Pathology

Volumn 109, Issue 2, 1998, Pages 153-162

  Shroyer, Kenneth R ^a   Thompson, L Chesney ^a   Enomoto, Takayuki ^b   Eskens, Joan L ^a   Shroyer, A Laurie ^c   McGregor, James A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Carcinoma; Cervix; Dysplasia; Telomerase

Indexed keywords

TELOMERASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX EPITHELIUM;

EID: 0031932663     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/109.2.153     Document Type: Article

References (69)

1. Blackburn EH. Structure and function of telomerase. Nature. 1991;350:569-573.
2. Zakian VA. Telomerase: beginning to understand the end. Science. 1995;270:1601-1607.
3. Rhyu MS. Telomeres, telomerase, and immortality. J Natl Cancer Inst. 1995;87:884-894.
4. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
5. Chadeneau C, Hay K, Hirte HW, et al. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 1995;55:2533-2536.
6. Tahara H, Nakanishi T, Kitamoto M, et al. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res. 1995;55:2734-2736.
7. Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer. Cancer Res. 1995;55:3258-3262.
8. Hiyama E, Gollahon L, Kataoka T, et al. Telomerase activity in human breast tumors. J Natl Cancer Inst. 1996;88:116-122.
9. Sommerfeld H-J, Meeker AK, Piatyszek MA, et al. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 1996;56:218-222.
10. Shroyer KR, Stephens JK, Silverberg SG, et al. Analysis of telomerase expression in normal endometrium, endometrial hyperplasia, and endometrial adenocarcinoma. Int J Gynecol Pathol. 1997;16:225-232.
11. Li Z-H, Salovaara R, Aaltonen LA, et al. Telomerase activity is commonly detected in hereditary nonpolyposis colorectal cancers. Am J Pathol. 1996;148:1075-1079.
12. Pao CC, Tseng CJ, Lin CY, et al. Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions. J Clin Oncol. 1997;15:1932-1937.
13. Anderson S, Shera K, Ihle J, et al. Telomerase activation in cervical cancer. Am J Pathol. 1997;151:25-31.
14. Kyo S, Takakura M, Ishikawa H, et al. Application of telomerase assay for the screening of cervical lesions. Cancer Res. 1997;57:1863-1867.
15. Cancer Facts & Figures - 1996. American Cancer Society, Atlanta, Ga.
16. Guidozzi F. Screening for cervical cancer. Obstet Gynecol Survey. 1996;51:247-252.
17. Birley HD. Human papillomaviruses, cervical cancer and the developing world. Ann Trop Med Parasit. 1995;89:453-463.
18. Tkeshelashvili VT, Bokhan JV, Kuznetzov VV, et al. Geographic peculiarities of endometrial and cervical cancer incidence in five continents. Eur J Gynaecol Oncol. 1993;14:89-94.
19. Richart RM. Cervical intraepithelial neoplasia. Pathol Ann. 1973;8:301-328.
20. Wright TC, Kurman RJ, Ferenczy A. Precancerous lesions of the cervix. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 4th ed. New York, NY: Springer-Verlag; 1994:229-232.
21. zur Hausen H. Papillomaviruses in anogenital cancer as a moderate dysplasia to understand the role of viruses in human cancers. Cancer Res. 1989;49:4677-4681.
22. Shroyer KR, Lovelace GS, Abarca ML, et al. Detection of human papillomavirus DNA by in situ hybridization and polymerase chain reaction in human papillomavirus equivocal and dysplastic cervical biopsies. Hum Pathol. 1993;24:1012-1016.
23. Fujinaga Y, Shimada M, Okazawa K, et al. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. J Gen Virol. 1991;72:1039-1044.
24. Park T-W, Fujiwara H, Wright TC. Molecular biology of cervical cancer and its precursors. Cancer Suppl 1995;76:1902-1913.
25. Petersen CS, Lindeberg H, Thomsen HL. Human papillomavirus types in cervical biopsy specimens from papsmear-negative women with external genital warts. Acta Obstet Gynecol Scand. 1991;70:69-71.
26. Nuovo GJ. Human papillomavirus DNA in genital tract lesions histologically negative for condylomata. Am J Surg Pathol. 1990;14:643-651.
27. Cox JT, Lorincz AT, Schiffman MH, et al. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 1995;172:946-954.
28. Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol. 1995;85:202-210.
29. Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy. Am J Obstet Gynecol. 1995;172:1150-1157.
30. Ferenczy A, Franco E, Arseneau J, et al. Diagnostic performance of Hybrid Capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study. Am J Obstet Gynecol. 1996;175:651-656.
31. Mitra AB, Murty VV, Li RG, et al. Allelotype analysis of cervical carcinoma. Cancer Res. 1994;54:4481-4487.
32. Mullokandov MR, Kholodilov NG, Atkin NB, et al. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res. 1996;56:197-205.
33. Mitra AB, Murty VV, Singh V, et al. Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J Natl Cancer Inst. 1995;87:742-745.
34. Bethwaite PB, Koreth J, Herrington CS, et al. Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical carcinoma. Br J Cancer. 1995;71:814-818.
35. Ocadiz R, Sauceda R, Cruz M, et al. High correlations between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix. Cancer Res. 1987;47:4173-4177.
36. Riou G, Barrois M, Le MG, et al. C-myc protooncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet. 1987;1(8536):761-763.
37. Bourhis J, Le MG, Barrois M, et al. Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol. 1990;8:1789-1796.
38. Baker VV, Hatch KD, Shingleton HM. Amplification of the c-myc proto-oncogene in cervical carcinoma. J Surg Oncol. 1988;39:225-228.
39. Bernard C, Mougin C, Laurent R, et al. Oncogene activation: an informative marker for the human papillomavirus lesion's severity. Cancer Detect Prevent. 1994;18:273-282.
40. Di Luca D, Costa S, Monini P, et al. Search for human papillomavirus, herpes simplex virus and c-myc oncogene in human genital tumors. Int J Cancer. 1989;43:570-577.
41. Ikenberg H, Schworer D, Pfleiderer A, et al. Lack of c-myc gene amplification in genital tumours with different HPV status. Lancet. 1987;2(8558):557.
42. Choo K-B, Chong K-Y, Chou H-F, et al. Analysis of the structure and expression of the c-myc oncogene in cervical tumor and in cervical tumor-derived cells. Biochem Biophys Res Commun. 1989;158:334-340.
43. Riou G, Barrois M, Sheng ZM, et al. Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers. Oncogene. 1988;3:329-333.
44. Koulos J, Wright TC, Follen MM, et al. Relationships between cKi-ras mutations, HPV types and prognostic indicators in invasive endocervical adenocarcinomas. Gynecol Oncol. 1993;48:364-369.
45. Willis G, Jennings B, Ball RV, et al. Analysis of ras point mutations and human papillomavirus 16 and 18 in cervical carcinomata and their metastases. Gynecol Oncol. 1993;49:359-364.
46. Van Le L, Stoerker J, Rinehart CA, et al. H-ras codon 12 mutation in cervical dysplasia. Gynecol Oncol. 1993;49:181-184.
47. Fujita M, Inoue M, Tanizawa O, et al. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res. 1992;52:5323-5328.
48. Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res. 1991;51:5308-5314.
49. Wright TC, Kurman RJ, Ferenczy A. Precancerous lesions of the cervix. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 4th ed. New York, NY: Springer-Verlag; 1994:244-254.
50. Wright TC, Kurman RJ, Ferenczy A. Carcinoma and other tumors of the cervix. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 4th ed. New York, NY: Springer-Verlag; 1994:287-289.
51. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem. 1976;72:248-254.
52. Rosner BA. Fundamentals of Biostatistics. Boston: Duxbury Press; 1982:225-253, 308-317.
53. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in rxc contingency tables. J Am Stat Assoc. 1983;78:427-434.
54. Yobs AR, Plott AE, Hicklin MD, et al. Retrospective evaluation of gynecologic cytodiagnosis II. Interlaboratory reproducibility as shown in rescreening large consecutive samples of reported cases. Acta Cytol. 1987;31:900-910.
55. Krieger P, Naryshkin S. Random rescreening of cytologic smears: a practical and effective component of quality assurance programs in both large and small cytology laboratories. Acta Cytol. 1994;38:291-298. Guest editorial.
56. Tabbara SO, Sidawy MK. Evaluation of the 10% rescreen of negative gynecologic smears as a quality assurance measure. Diagn Cytopathol. 1996;14:84-86.
57. Slagel DD, Zaleski S, Cohen MB. Efficacy of automated cervical cytology screening. Diag Cytopathol. 1995;13:26-30.
58. Hallam N, Green J, Gibson P, et al. Prevalence of HPV cervical infection in a family planning clinic determined by polymerase chain reaction and dot blot hybridisation. J Med Virol. 1991;34:154-158.
59. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991;265:472-477.
60. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis. 1993;20:274-278.
61. Hildesheim A, Gravitt P, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-income women in Washington, DC. Sex Transm Dis. 1993;20:279-285.
62. Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico Student Health Center. Sex Transm Dis. 1993;20:286-289.
63. Boon ME, Kok LP. Neural network processing can provide means to catch errors that slip through human screening of pap smears. Diagn Cytopathol. 1993;9:411-416.
64. Koss LG, Lin E, Schreiber K, et al. Evaluation of the PAPNET cytologic screening system for quality control of cervical smears. Am J Clin Pathol. 1994;101:220-229.
65. Sherman ME, Mango LJ, Kelly D, et al. PAPNET analysis of reportedly negative smears preceding the diagnosis of a high-grade squamous intraepithelial lesion or carcinoma. Mod Pathol. 1994,7:578-581.
66. Mango LJ. Neuromedical Systems, Inc. Acta Cytol. 1996;40:53-59.
67. Colgan TJ, Pattern SF, Lee JSJ. A clinical trial of the AutoPap 300 QC System for quality control of cervicovaginal cytology in the clinical laboratory. Acta Cytol. 1995;39:1191-1198.
68. Wilbur DC, Bonfiglio TA, Rutkowski MA, et al. Sensitivity of the AutoPap 300 QC System for cervical cytologic abnormalities. Biopsy data confirmation. Acta Cytol. 1996;40:127-132.
69. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA. 1995;92:9082-9086.